Endocrine Abstracts

Adrenocortical carcinoma (ACC) is a very severe endocrine malignancy with poor prognosis. While cancer immunotherapies have revolutionized the treatment of several cancer entities, the results of initial studies of different immune checkpoint inhibitors in ACC were heterogeneous and clinically substantial responses were observed only in a subset of patients. Expression of immune checkpoint molecules - programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T Lymphocytes...

Introduction: The genetic mechanisms underlying adrenocortical tumor development are still largely unknown. We used high-resolution single nucleotide polymorphism (SNP) microarrays to detect copy number alterations (CNAs) and copy neutral losses of heterozygosity (cnLOH) in cortisol-secreting adrenocortical adenomas (ACAs). We focused on microalterations aiming to discover new candidate genes involved in early tumorigenesis and/or autonomous cortisol secretion.<p class="ab...

In recent years, it was demonstrated that tumor infiltrating and circulating regulatory and cytotoxic T-cells are associated with clinical outcome in several solid tumors. However, their role in adrenocortical carcinoma (ACC) was never studied, although 60% of these tumors secrete autonomously cortisol, a well-established potent immunosuppressant that most likely influences the balance between different T-cells.Firstly, we analyzed the circulating regula...

Purpose: Mitotane is the reference systemic therapy for adrenocortical carcinoma (ACC), but its mechanism of action and possible predictors of treatment response remain poorly defined. Our aim was to evaluate the gene expression of ribonucleotide reductase large subunit 1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) in ACC as potential biomarkers for clinical outcome and response to mitotane.Experimental design: Forty-five and 47 tiss...